For the fourth quarter (Q4) ended March 31, 2021, the company recorded a net revenue of Rs359.7cr, on a consolidated basis, as against Rs477.2cr during Q4FY20. The profit after tax (PAT), on a consolidated basis, was recorded as Rs53cr for the quarter, as against Rs93.2cr same quarter last year.
“In spite of significant negative impact of the pandemic on the base business, the company was able to sustain its revenue during the year. The company expects strong growth during the current year due to multiple high value product launches in the USA, rebound in domestic India business with new products and contribution from Crop Health division,” company said in a filing on Thursday.
Natco Pharma Ltd ended at Rs1,081.15 per piece down by Rs50.1 or 4.43% from its previous closing of Rs1,131.25 per piece on the BSE.